2006 Pipeline Budget: $5.3 billion (â‚¬3.62)
2007 Pipeline News: One of Merck's biggest pipeline hopes is anacetrapib, a drug designed to increase good cholesterol and decrease bad cholesterol. Sound familiar? That's because anacetrapib is a CTEP inhibitor--the same class of drug as Pfizer's failed torcetrapib. The drug, which is currently in Phase II, could tap into a $15 billion market.
In 2007 Merck received FDA approval of HIV drug Isentress, filed an NDA for Cordaptive (a cholesterol drug that combines a known ingredient with a new one that reduces the risk of flushing). The company also inked a billion-dollar pact for Ariad's cancer drug AP23573, which is in late-stage testing for metastatic sarcomas. And Sanofi-Aventis better get its act together with Acomplia, because Merck's obesity drug taranabant is in Phase III and could be up for FDA approval in 2008.
MK-0518 (raltegravir) - HIV
MK-0517 - chemotherapy-induced nausea and vomiting (approvable)
Full Pipeline Site: Link